Ph.D. biologist, serial entrepreneur, director, consultant and author. More than three decades experience working with leading scientists and clinicians to create substantial commercial value from inventions related to genome analysis. During that time commercialized life science products impacting the lives of millions, raising more than $100 million in startup and early stage funding, and leading businesses to create more than $1 billion in market value for shareholders. https://www.roseventures.net/bloghttps://us.amazon.com/Cant-Tame-Mongoose-Genomics-Entrepreneur-ebook/dp/B0CNKX1HPH/ref=zg_bsnr_g_154796011_d_sccl_34/139-2385610-8334545?psc=1
-
PresidentRose Ventures Inc. Jun 2008 - PresentRose Ventures works with early stage companies developing innovative, high-impact life science products and services. We bring a wealth of direct operational expertise, a track record of success, and a network of life scientists, entrepreneurs and contacts in industry, academia, finance and government that can be leveraged to facilitate growth of the most promising emerging companies in the space. Beyond financing or advisory services, portfolio companies and clients benefit by tapping into a network that can help them execute on their business plans and create value for all stake holders.
-
DirectorXeno Biosciences 2021 - PresentCambridge, UsXeno Biosciences is a drug development company dedicated to finding safe and effective treatments for obesity and metabolic diseases. -
Senior FellowThe Council On Strategic Risks 2020 - PresentWashington, District Of Columbia, UsContributing to CSR’s Alliance to End Biological Threats. -
DirectorSerumdpt 2022 - 2024SerumDPT Bioscience have created the first device enabling real-time isolation of plasma or serum from drawn blood. -
DirectorInvenra 2012 - Aug 2023Madison, Wisconsin, UsInvenra is a biotechnology company focused on the discovery and development of multi-specific antibodies for immuno-oncology and autoimmune disorders. -
Ceo And Co-FounderEurofins Transplant Genomics 2013 - 2021Framingham, Ma, UsCo-founder, President and CEO of Transplant Genomics Inc. (acquired by Eurofins in 2019), whose TruGraf® blood gene expression tests enable doctors to rule out silent rejection in kidney transplant recipients. -
Chief Executive OfficerRoche Nimblegen Inc. 2003 - 2008UsServed as CEO of NimbleGen Systems, a genomics tools company acquired by Roche in 2007 -
Chief Operating Officer And Co-FounderGenetic Microsystems 1997 - 2001Microarray instrumentation company that was acquired by Affymetrix in 2000 -
Pcr Business DirectorPerkin-Elmer / Applied Biosystems 1989 - 1994Directed the PCR business for Perkin-Elmer and Applied Biosystems (now Thermo Fisher) during its most dynamic growth phase in the 1990s.
-
Director Dna Products And ServicesCollaborative Research 1986 - 1989Tyler, Texas, UsBuilt and directed one of the first DNA diagnostic testing laboratory businesses, working in areas ranging from genetic testing, to forensic analysis, to early commercial efforts to map the human genome
Stan Rose Education Details
-
Massachusetts Institute Of TechnologyGeneral -
Cornell UniversityPsychology
Frequently Asked Questions about Stan Rose
What company does Stan Rose work for?
Stan Rose works for Xeno Biosciences
What is Stan Rose's role at the current company?
Stan Rose's current role is Serial Entrepreneur, Director, Author.
What schools did Stan Rose attend?
Stan Rose attended Massachusetts Institute Of Technology, Cornell University.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial